Real-world study tests migraine drug atogepant over 12 months in tough-to-treat patients

NCT ID NCT07699549

First seen Jul 13, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study follows over 500 adults with migraine who have not responded well to other preventive treatments. Participants take atogepant as prescribed by their doctor and are monitored for a year to see how well it reduces headache and migraine days, and how long they stay on the medication. The goal is to understand if atogepant works in everyday clinical practice for people with a high burden of migraine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
atogepant
What this could lead to
If successful, this could confirm atogepant as a reliable long-term preventive option for people with hard-to-treat migraine.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and real-world variability. It is also limited to a specific population with prior treatment failures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEADACHE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Headache headache disorder migraine disorder Prescription Drug Overuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Universitario de La Princesa

    Madrid, Madrid, 28006, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.